Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 51 results
Filters: First Letter Of Title is I  [Clear All Filters]
Found 51 results.

2013

Zhang X, Hunt PW, Hammer SM, Cespedes MS, Patterson KB, Bosch RJ. "Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment." HIV Clin Trials. 2013;14(2):61-7.
Lok JJ, Hunt PW, Collier AC, et al. "The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy." AIDS. 2013;27(13):2101-10.
Li JZ, Paredes R, Ribaudo HJ, et al. "Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure." J. Infect. Dis.. 2013;207(6):893-7.
Ribaudo HJ, Daar ES, Tierney C, et al. "Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202." J. Infect. Dis.. 2013;207(3):420-5.
Godfrey CC, Michelow PM, Godard M, et al. "Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks." Am. J. Clin. Pathol.. 2013;140(6):881-9.
Branch AD, Kang M, Hollabaugh K, Wyatt CM, Chung RT, Glesby MJ. "In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use." Am. J. Clin. Nutr.. 2013;98(2):423-9.
Vandergeeten C, Fromentin R, DaFonseca S, et al. "Interleukin-7 promotes HIV persistence during antiretroviral therapy." Blood. 2013;121(21):4321-9.
Hochreiter J, Lapham J, Wong-Staal F, et al. "ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection." Antivir. Ther. (Lond.). 2013;18(3):329-36.

2011

Linas BP, Wang B, Smurzynski M, et al. "The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort." J. Viral Hepat.. 2011;18(7):506-12.
Krishnan S, Schouten JT, Jacobson DL, et al. "Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis." Oncology. 2011;80(1-2):42-9.
Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE. "The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin." Aliment. Pharmacol. Ther.. 2011;33(11):1234-44.
Krishnan S, Wu K, Smurzynski M, et al. "Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis." HIV Clin Trials. 2011;12(4):190-200.
Taylor LE, Holubar M, Wu K, et al. "Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials." Clin. Infect. Dis.. 2011;52(6):812-8.
Haubrich RH, Riddler SA, Ribaudo H, et al. "Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection." AIDS. 2011;25(18):2269-78.
Hu Z, Kuritzkes DR. "Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1." J. Virol.. 2011;85(21):11309-14.

Pages